IBIO, INC. (IBIO) Debt Components
- 2025-09-30: Secured Debt, CurrentUSD $16.00K; Notes Payable, CurrentUSD $706.00K.
- 2025-06-30: Secured Debt, CurrentUSD $64.00K; Notes Payable, CurrentUSD $766.00K.
- 2025-03-31: Secured Debt, CurrentUSD $110.00K; Notes Payable, CurrentUSD $824.00K.
- 2024-12-31: Secured Debt, CurrentUSD $155.00K; Notes Payable, CurrentUSD $237.00K.
IBIO, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Secured Debt, Current USD | Notes Payable, Current USD |
|---|---|---|
| 2025-09-30 | $16.00K | $706.00K |
| 2025-06-30 | $64.00K | $766.00K |
| 2025-03-31 | $110.00K | $824.00K |
| 2024-12-31 | $155.00K | $237.00K |
| 2024-09-30 | $182.00K | $227.00K |
| 2024-06-30 | $178.00K | $218.00K |
| 2024-03-31 | (m) | $12.65M |
| 2023-12-31 | (m) | $12.65M |
| 2023-09-30 | (m) | $12.62M |
| 2023-06-30 | $160.00K | (m) |
| 2023-06-30 | (m) | $12.94M |
| 2023-03-31 | (m) | $13.70M |
| 2022-12-31 | (m) | $16.01M |
| 2022-09-30 | (m) | $22.20M |
| 2022-06-30 | (m) | $22.16M |
| 2022-03-31 | (m) | $0.00 |
| 2021-12-31 | (m) | $0.00 |
| 2021-09-30 | (m) | $0.00 |
| 2021-06-30 | (m) | $600.00K |
| 2021-03-31 | (m) | $566.00K |
| 2020-12-31 | (m) | $465.00K |
| 2020-09-30 | (m) | $362.00K |
| 2020-06-30 | (m) | $261.00K |
| 2020-03-31 | (m) | $1.20M |
| 2019-06-30 | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |